Company Filing History:
2 out of 16 
2 out of 856 
Years Active: 2017-2018
Title: Innovations by Koji Hase in Microbiota Research
Introduction
Koji Hase is a notable inventor based in Yokohama, Japan. He has made significant contributions to the field of microbiota research, particularly in the development of compositions for the treatment of various diseases. With a total of two patents to his name, Hase's work focuses on the therapeutic potential of bioactive molecules derived from microbiota.
Latest Patents
Hase's latest patents include compositions containing combinations of bioactive molecules derived from microbiota for the treatment of diseases. These compositions consist of bioactive molecules derived from the microbiota of mammals. When administered orally with a colonic delivery system, these compositions are useful for the prophylaxis and treatment of diseases, particularly inflammatory, autoimmune, and infectious diseases. The formulations comprise combinations of small molecules and bacterial antigens, which are designed to be delivered to the colon. The use of these compositions can result in various beneficial outcomes, including the induction of immune tolerance, strengthening of the gut mucosal barrier integrity, reduction of inflammation, and amelioration of disease states caused by inflammation, autoimmune reactions, or infectious agents.
Career Highlights
Throughout his career, Koji Hase has worked with prominent organizations such as Vedanta Biosciences, Inc. and Riken Corporation. His work in these companies has allowed him to advance his research and contribute to the understanding of microbiota's role in health and disease.
Collaborations
Hase has collaborated with notable individuals in his field, including Kenya Honda and Bernat Olle. These collaborations have further enriched his research and innovation efforts.
Conclusion
Koji Hase's contributions to microbiota research and his innovative patents highlight the potential of bioactive molecules in treating various diseases. His work continues to pave the way for advancements in therapeutic applications derived from microbiota.